Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism

König J, Wyllie S, Wells G, Stevens MF, Wyatt PG, Fairlamb AH (2011)
The Journal of biological chemistry 286(10): 8523-8533.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ;
Abstract
Better drugs are urgently needed for the treatment of African sleeping sickness. We tested a series of promising anticancer agents belonging to the 4-substituted 4-hydroxycyclohexa-2,5-dienones class ("quinols") and identified several with potent trypanocidal activity (EC(50) < 100 nM). In mammalian cells, quinols are proposed to inhibit the thioredoxin/thioredoxin reductase system, which is absent from trypanosomes. Studies with the prototypical 4-benzothiazole-substituted quinol, PMX464, established that PMX464 is rapidly cytocidal, similar to the arsenical drug, melarsen oxide. Cell lysis by PMX464 was accelerated by addition of sublethal concentrations of glucose oxidase implicating oxidant defenses in the mechanism of action. Whole cells treated with PMX464 showed a loss of trypanothione (T(SH)(2)), a unique dithiol in trypanosomes, and tryparedoxin peroxidase (TryP), a 2-Cys peroxiredoxin similar to mammalian thioredoxin peroxidase. Enzyme assays revealed that T(SH)(2), TryP, and a glutathione peroxidase-like tryparedoxin-dependent peroxidase were inhibited in time- and concentration-dependent manners. The inhibitory activities of various quinol analogues against these targets showed a good correlation with growth inhibition of Trypanosoma brucei. The monothiols glutathione and L-cysteine bound in a 2:1 ratio with PMX464 with K(d) values of 6 and 27 μM, respectively, whereas T(SH)(2) bound more tightly in a 1:1 ratio with a K(d) value of 430 nM. Overexpression of trypanothione synthetase in T. brucei decreased sensitivity to PMX464 indicating that the key metabolite T(SH)(2) is a target for quinols. Thus, the quinol pharmacophore represents a novel lead structure for the development of a new drug against African sleeping sickness.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

König J, Wyllie S, Wells G, Stevens MF, Wyatt PG, Fairlamb AH. Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of biological chemistry. 2011;286(10):8523-8533.
König, J., Wyllie, S., Wells, G., Stevens, M. F., Wyatt, P. G., & Fairlamb, A. H. (2011). Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of biological chemistry, 286(10), 8523-8533.
König, J., Wyllie, S., Wells, G., Stevens, M. F., Wyatt, P. G., and Fairlamb, A. H. (2011). Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of biological chemistry 286, 8523-8533.
König, J., et al., 2011. Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of biological chemistry, 286(10), p 8523-8533.
J. König, et al., “Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism”, The Journal of biological chemistry, vol. 286, 2011, pp. 8523-8533.
König, J., Wyllie, S., Wells, G., Stevens, M.F., Wyatt, P.G., Fairlamb, A.H.: Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism. The Journal of biological chemistry. 286, 8523-8533 (2011).
König, Janine, Wyllie, Susan, Wells, Geoffrey, Stevens, Malcolm F, Wyatt, Paul G, and Fairlamb, Alan H. “Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism”. The Journal of biological chemistry 286.10 (2011): 8523-8533.
This data publication is cited in the following publications:
This publication cites the following data publications:

5 Citations in Europe PMC

Data provided by Europe PubMed Central.

Whole-organism high-throughput screening against Trypanosoma brucei brucei.
Jones AJ, Avery VM., Expert Opin Drug Discov 8(5), 2013
PMID: 23540598
Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.
Jones DC, Alphey MS, Wyllie S, Fairlamb AH., Mol. Microbiol. 86(1), 2012
PMID: 22857512
Quinol derivatives as potential trypanocidal agents.
Capes A, Patterson S, Wyllie S, Hallyburton I, Collie IT, McCarroll AJ, Stevens MF, Frearson JA, Wyatt PG, Fairlamb AH, Gilbert IH., Bioorg. Med. Chem. 20(4), 2012
PMID: 22264753
Peroxiredoxins in parasites.
Gretes MC, Poole LB, Karplus PA., Antioxid. Redox Signal. 17(4), 2012
PMID: 22098136

57 References

Data provided by Europe PubMed Central.

The high resolution crystal structure of recombinant Crithidia fasciculata tryparedoxin-I.
Alphey MS, Leonard GA, Gourley DG, Tetaud E, Fairlamb AH, Hunter WN., J. Biol. Chem. 274(36), 1999
PMID: 10464297
Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei: photoreduction of the redox disulfide using synchrotron radiation and evidence for a conformational switch implicated in function.
Alphey MS, Gabrielsen M, Micossi E, Leonard GA, McSweeney SM, Ravelli RB, Tetaud E, Fairlamb AH, Bond CS, Hunter WN., J. Biol. Chem. 278(28), 2003
PMID: 12707277
Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi.
Jones DC, Ariza A, Chow WH, Oza SL, Fairlamb AH., Mol. Biochem. Parasitol. 169(1), 2010
PMID: 19747949
2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications.
Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH., Trends Mol Med 11(12), 2005
PMID: 16290020
Can we rationally design promiscuous drugs?
Hopkins AL, Mason JS, Overington JP., Curr. Opin. Struct. Biol. 16(1), 2006
PMID: 16442279
Network pharmacology: the next paradigm in drug discovery.
Hopkins AL., Nat. Chem. Biol. 4(11), 2008
PMID: 18936753

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 21212280
PubMed | Europe PMC

Search this title in

Google Scholar